TLSA

SEC filing TLSA Completes Enrollment in Phase 2a Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis, 48 Patients Enrolled

12d ago

News Tiziana says updated data for multiple sclerosis therapy shows long-term safety

14d ago

SEC filing TLSA Reports Positive Clinical Data for Intranasal Foralumab, 64% of Patients Show Clinically Meaningful Fatigue Improvement, Favorable EDSS Stabilization Trend

14d ago

SEC filing TLSA Reports Positive Preclinical Data on Intranasal Anti-CD3 for Long COVID Brain Fog, Shows Neuroinflammation Reduction and Cognitive Improvement in Mouse Model, Co-Authored by Yale’s Iwasaki and Harvard’s Weiner, Study Published on bioRxiv, Highlights Potential for Non-Invasiv

47d ago

News Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

136d ago

News Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

136d ago

News Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

137d ago

Scanner Unusual volume (z=5.5)

168d ago

News Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

168d ago

Scanner Unusual volume (z=5.7)

169d ago

Scanner Unusual volume (z=5.7)

170d ago

Scanner Unusual volume (z=5.7)

171d ago